Tianjin Nine Health Electronic Co., Ltd. 2025 Annual Report Summary
Securities Code: 002432 Securities Abbreviation: Nine Health Announcement No.: 2026-015
I. Important Notes This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial condition, and future development plans, investors should carefully read the full annual report on the designated media of the China Securities Regulatory Commission. All directors attended the board meeting that reviewed this report. Non-standard Audit Opinion Notice □ Applicable Not Applicable Board of Directors' Review of the Profit Distribution Proposal or Capital Reserve to Share Capital Increase Proposal for the Reporting Period ☑ Applicable Not Applicable Whether to use capital reserve to increase share capital □ Yes No The profit distribution proposal reviewed and approved by the company's board of directors for this reporting period is: based on the total share capital on the equity registration date for the future implementation of the distribution plan, excluding the shares in the treasury stock repurchase account, a cash dividend of RMB 16.5 yuan (including tax) per 10 shares will be distributed to all shareholders, with 0 bonus shares (including tax), and no capital reserve to increase share capital. Board of Directors' Resolution on Preferred Share Profit Distribution Proposal for the Reporting Period □ Applicable Not Applicable
II. Company Basic Information
- Company Profile Stock Abbreviation: Nine Health Stock Code: 002432 Stock Exchange: Shenzhen Stock Exchange Previous Stock Abbreviation (if any): None
Name: Wu Tong Office Address: Nankai District, Tianjin, Nankai Industrial Park, Yaan Road, Jinping Road No. 3 Fax: 022-87612379 Tel: 022-87611660-8220 Email: ir@jiuan.com
Contact Person and Contact Information Secretary of the Board: Li Fan Securities Affairs Representative: Wu Tong Address: Nankai District, Tianjin, Nankai Industrial Park, Yaan Road, Jinping Road No. 3 Fax: 022-87612379 Tel: 022-87611660-8220 Email: ir@jiuan.com
- Business or Product Introduction for the Reporting Period The company has established a dual-core business development model: a primary business in medical health operations + a secondary business in large-asset allocation investment.